Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
复制标题
血液淋巴细胞与单核细胞比率可识别接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤的高危患者
DOI：
10.1371/journal.pone.0041658
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Jiang WQ
中科院分区：
文献类型：
--
作者：
Li ZM;Huang JJ;Xia Y;Sun J;Huang Y;Wang Y;Zhu YJ;Li YJ;Zhao W;Wei WX;Lin TY;Huang HQ;Jiang WQ
近年来的研究表明免疫微环境与淋巴瘤生物学之间存在相关性。本研究旨在探讨利妥昔单抗时代弥漫性大b细胞淋巴瘤（DLBCL）中免疫相关淋巴细胞/单核细胞比率（LMR）的预后意义。我们分析了438例新诊断的DLBCL患者的回顾性数据，这些患者接受了利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和强的松（R-CHOP）治疗。我们随机选择200例患者（训练集），通过受试者工作特征（ROC）曲线分析产生LMR的截断值。然后在测试集（n = 238）和所有患者（n = 438）中分析LMR以进行验证。训练集中ROC曲线确定的生存分析LMR截止值为2.6。低LMR患者往往有更多的不良临床特征。诊断时的低LMR与DLBCL的较差生存率相关，并且也可以在低风险IPI类别中识别高风险患者。多变量分析确定LMR是测试组和所有患者生存的独立预后因素。基线LMR是免疫微环境的替代生物标志物，在接受R-CHOP治疗的DLBCL患者中是一个有效的预后因素。需要进一步的前瞻性研究来证实我们的发现。
Background Recent research has shown a correlation between immune microenvironment and lymphoma biology. This study aims to investigate the prognostic significance of the immunologically relevant lymphocyte-to-monocyte ratio (LMR), in diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Methodology/Principal Findings We analyzed retrospective data from 438 newly diagnosed DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. We randomly selected 200 patients (training set) to generate a cutoff value for LMR by receiver operating characteristic (ROC) curve analysis. LMR was then analyzed in a testing set (n = 238) and in all patients (n = 438) for validation. The LMR cutoff value for survival analysis determined by ROC curve in the training set was 2.6. Patients with low LMR tended to have more adverse clinical characteristics. Low LMR at diagnosis was associated with worse survival in DLBCL, and could also identify high-risk patients in the low-risk IPI category. Multivariate analysis identified LMR as an independent prognostic factor of survival in the testing set and in all patients. Conclusions/Significance Baseline LMR, a surrogate biomarker of the immune microenvironment, is an effective prognostic factor in DLBCL patients treated with R-CHOP therapy. Future prospective studies are required to confirm our findings.
登录
查看更多内容
影响因子：
6.5
作者：
Porrata, Luis F.;Ristow, Kay;Markovic, Svetomir N.
通讯作者：
Markovic, Svetomir N.
影响因子：
50.5
作者：
Bari, A.;Marcheselli, L.;Cox, M. C.
通讯作者：
Cox, M. C.
影响因子：
20.3
作者：
Alizadeh, Ash A.;Gentles, Andrew J.;Levy, Ronald
通讯作者：
Levy, Ronald
影响因子：
6.4
作者：
Ishii, Hideyuki;Takahara, Miki;Klein, Eva
通讯作者：
Klein, Eva
DOI：
10.3324/haematol.2011.050138
发表时间：
2012-02-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Porrata, Luis F.;Ristow, Kay;Markovic, Svetomir N.
通讯作者：
Markovic, Svetomir N.